HighPoint Advisor Group LLC Has $16.06 Million Stake in Eli Lilly and Company (NYSE:LLY)

HighPoint Advisor Group LLC lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 6.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,741 shares of the company’s stock after selling 1,294 shares during the quarter. Eli Lilly and Company comprises approximately 0.9% of HighPoint Advisor Group LLC’s investment portfolio, making the stock its 20th largest holding. HighPoint Advisor Group LLC’s holdings in Eli Lilly and Company were worth $16,060,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Principal Financial Group Inc. boosted its position in Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after purchasing an additional 60,306 shares during the period. Tradition Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 14.0% in the 3rd quarter. Tradition Wealth Management LLC now owns 1,403 shares of the company’s stock worth $1,243,000 after purchasing an additional 172 shares during the period. Timber Creek Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Timber Creek Capital Management LLC now owns 12,632 shares of the company’s stock valued at $11,191,000 after buying an additional 86 shares in the last quarter. Plotkin Financial Advisors LLC bought a new stake in Eli Lilly and Company in the third quarter worth $845,000. Finally, Erste Asset Management GmbH purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at $35,618,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $820.30 on Monday. The company’s 50 day moving average is $844.31 and its 200 day moving average is $835.77. The company has a market cap of $777.78 billion, a PE ratio of 70.05, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its Board of Directors has approved a stock repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a research note on Friday, January 17th. Bank of America reiterated a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Wells Fargo & Company raised their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Finally, Citigroup dropped their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.